Brazil's Hypermarcas sells drug assets to Merck; Sanofi to unload Paris R&D park; Teva recruits new vice chairman;

@FiercePharma: Tuesday's best-read new news: Teva braces for $550M hit from Copaxone generics. Story | Follow @FiercePharma

@EricPFierce: The here and now of track and trace. Editor's corner | Follow @EricPFierce

@CarlyHFierce: Tuesday's most popular special report: Top 10 generics makers by 2012 revenue. Report | Follow @CarlyHFierce

> The Brazilian drugmaker and consumer goods manufacturer Hypermarcas plans to sell off some of its drug-manufacturing rights and other assets to Merck's ($MRK) Brazilian unit. Report

> Sanofi ($SNY) plans to sell its Paris life sciences park to the public investment group Caisse de Depots in a two-stage deal to be wrapped up by 2015. Report

> Israel Corp. Chairman Amir Elstein will step down at the end of the year to join Teva Pharmaceutical Industries' ($TEVA) board as vice chair. Report

> Zogenix ($ZGNX) won FDA approval for a new 4 mg dose of its Sumavel migraine and cluster headache injection. Release

> Popular stomach-acid drugs known as proton-pump inhibitors are linked with an increased risk of vitamin B12 deficiency, which can lead to a variety of other health problems. Report (sub. req.)

> Endo Health Solutions ($ENDP) tapped Arthur Higgins to join its board of directors, while Joseph Scodari will retire from the board. Release

Medical Device News

@FierceMedDev: Echo Therapeutics finds a China partner for its glucose monitor, satisfies an angry investor. Article | Follow @FierceMedDev

@MarkHFierce: Presenting, our latest issue of FierceDiagnostics--check it out, and tell a friend. Issue | Follow @MarkHFierce

@MichaelGFierce: Sanofi's Genzyme nets FDA priority review for its oral Gaucher pill. More from FierceDrugDelivery | Follow @MichaelGFierce

@GalenMoore: Imploding microbubbles give transdermal patch an edge over arthritis. Story | Follow @GalenMoore

> Ireland resists tougher EU device regulations. More

> LabCorp predicts another 'difficult' year in 2014 as revenues lag. Article

> After losing a $27M judgment to St. Jude Medical, AccessClosure touts a win. News

Biotech News

@FierceBiotech: Big Biopharmas help fuel $26M round for Sutro's antibody R&D work. News | Follow @FierceBiotech

@JohnCFierce: GEN ranks VCs by total funds under management. Hmmmm. Feature via GEN | Follow @JohnCFierce

@DamianFierce: With fresh hopes and a bunch of new safety data, Orexigen is going back to the FDA with Contrave. Story | Follow @DamianFierce

@EmilyMFierce: 1 in 100 cancers are associated with a particular gene mutation, according to a Sanger Institute study. Story from FierceBiotech Research  | Follow @EmilyMFierce

> Avanir hits the skids after its pain drug flunks a mid-stage study. More

> Celgene chips in $20M to extend Agios cancer deal. Story

Diagnostics News

> French company unveils prenatal test based on licensed Sequenom tech. Story

> DioGenix's venture round fuels expanded trial for MS molecular Dx test. Report

> New Hologic CEO pledges to grow, and not sell, the women's health Dx company. More

> Foundation Medicine shows test's worth as a highly specific blood cancer screening tool. Article

> Invitae's $40M Series E adds rocket fuel to genetic test expansion plans. News

> Sequenta expands reach of ultrasensitive cancer Dx test. Item

Biomarkers News

> Biomarker points to aggressive breast cancer in black women. Story

> Cellular switch biomarker predicts prostate cancer's spread. Piece

> In China, lung cancer biomarker testing is on the rise. More

> Gene biomarker may determine whether some depression drugs will work. News

> New tech promises to speed up biomarker validation. Article

> Inflammatory marker presents a new target for obesity drug developers. Item

Drug Delivery News

> Alliqua CEO: Celgene deal vaults us to 'another level of respectability'. Article

> Protein 'crossing guard' carries Alzheimer's drug past the blood-brain barrier. More

> Imploding microbubbles give transdermal patch an edge for arthritis drugs. News

> Sanofi's Genzyme nets FDA priority review for its oral Gaucher pill. Report

> Rutgers team delivers RNA to weaken drug-resistant ovarian cancer. Story

> Swedish team: Omega-3 fatty acids cross blood-brain barrier for possible Alzheimer's treatment. Item

And Finally… A former Pfizer ($PFE) factory in Flushing, NY, has traded medicine for chocolate. Report

 

 

 

 

Suggested Articles

Sixteen years after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

In a non-randomized study in China, Avigan cleared virus after a median 4 days, significantly shorter than the 11 days observed for AbbVie's Kaletra.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.